Increased alcohol consumption in rats after subchronic antidepressant treatment

International Journal of Neuropsychopharmacology

Volumn 16, Issue 8, 2013, Pages 1809-1818

  Alén, Francisco ^a,b   Orio, Laura ^b   Gorriti, Miguel Á ^a   De Heras, Raquel Gómez ^a   Ramírez López, María Teresa ^a   Pozo, Miguel Ángel ^c   De Fonseca, Fernando Rodríguez ^b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c INSTITUTO PLURIDISCIPLINAR   (Spain)

Author keywords

Alcoholism; Antidepressants; Fluoxetine; Rat; Relapse; Venlafaxine

Indexed keywords

AMPHETAMINE; FLUOXETINE; VENLAFAXINE;

ALCOHOL CONSUMPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; MALE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHOPHARMACOLOGY; RAT; SENSITIZATION; TREATMENT DURATION; TREATMENT RESPONSE;

ALCOHOL DRINKING; ALCOHOLS; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ADDICTIVE; BODY WEIGHT; CONDITIONING, OPERANT; CYCLOHEXANOLS; DISEASE MODELS, ANIMAL; FLUOXETINE; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; SELF ADMINISTRATION; TIME FACTORS;

EID: 84882992142     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000217     Document Type: Article

References (81)

1. Alen F, Santos A, Moreno-Sanz G, Gonzalez-Cuevas G, Gine E, Franco-Ruiz L, Navarro M, Lopez-Moreno JA (2009) Cannabinoid-induced increase in relapse-like drinking is prevented by the blockade of the glycine-binding site of N-methyl-D-aspartate receptors. Neuroscience 158: 465-473.
2. Andrews JM, Ninan PT, Nemeroff CB (1996) Venlafaxine: a novel antidepressant that has a dual mechanism of action. Depression 4: 48-56.
3. Appolinario JC, Bueno JR, Coutinho W (2004) Psychotropic drugs in the treatment of obesity: what promise? CNS Drugs 18: 629-651.
4. Ashton CH, Young AH (1999) SSRIs, drug withdrawal and abuse: problem of treatment? In: Selective serotonin reuptake inhibitors (SSRIs): Past, present and future (Stanford SC, ed), pp65-80. Austin, TX: R.G. Landes Company
5. Baldessarini RJ, Ghaemi SN, Viguera AC (2002) Tolerance in antidepressant treatment. Psychother Psychosom 71: 177-179.
6. Barrot M, Wallace DL, Bolanos CA, Graham DL, Perrotti LI, Neve RL, Chambliss H, Yin JC, Nestler EJ (2005) Regulation of anxiety and initiation of sexual behavior by CREB in the nucleus accumbens. Proc Natl Acad Sci USA 102: 8357-8362.
7. Blier P, Tremblay P (2006) Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 67 (Suppl.) 4: 8-13.
8. Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M (2009) Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing 'deprivation-amplification relapse therapy' (DART). Postgrad Med 121: 176-196.
9. Brenes JC, Fornaguera J (2009) The effect of chronic fluoxetine on social isolation-induced changes on sucrose consumption, immobility behavior, and on serotonin and dopamine function in hippocampus and ventral striatum. Behav Brain Res 198: 199-205.
10. Bussing R, Levin GM (1993) Methamphetamine and fluoxetine treatment of a child with attention-deficit hyperactivity disorder and obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 3: 53-58.
11. Chick J, Aschauer H, Hornik K (2004) Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 74: 61-70.
12. Ciraulo DA, Barnhill JG, Jaffe JH (1988) Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43: 509-518.
13. Ciulla L, Menezes HS, Bueno BB, Schuh A, Alves RJ, Abegg MP (2007) Antidepressant behavioral effects of duloxetine and fluoxetine in the rat forced swimming test. Acta Cir Bras 22: 351-354.
14. Clavenna A, Rossi E, DeRosa M, Bonati M (2007) Use of psychotropic medications in Italian children and adolescents. Eur J Pediatr 166: 339-347.
15. Clerc GE, Ruimy P, Verdeau-Palles J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The venlafaxine French inpatient study group. Int Clin Psychopharmacol 9: 139-143.
16. Collu M, Poggiu AS, Devoto P, Serra G (1997) Behavioural sensitization of mesolimbic dopamine D2 receptors in chronic fluoxetine-treated rats. Eur J Pharmacol 322: 123-127.
17. Coupland NJ, Bell CJ, Potokar JP (1996) Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16: 356-362.
18. Darke S, Ross J (2000) The use of antidepressants among injecting drug users in Sydney, Australia. Addiction 95: 407-417.
19. da-Silva VA, Altenburg SP, Malheiros LR, Thomaz TG, Lindsey CJ (1999) Postnatal development of rats exposed to fluoxetine or venlafaxine during the third week of pregnancy. Braz J Med Biol Res 32: 93-98.
20. Dean AJ (2002) Are antidepressants addictive? Drug Alcohol Rev 21: 317-319.
21. Depont F, Rambelomanana S, Le Puil S, Begaud B, Verdoux H, Moore N (2003) Antidepressants: psychiatrists' opinions and clinical practice. Acta Psychiatr Scand 108: 24-31.
22. Deussing JM (2006) Animal models of depression. Drug Discov Today: Dis Models 3: 375-383.
23. De Vry J, Maurel S, Schreiber R, de Beun R, Jentzsch KR (1999) Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. Eur Neuropsychopharmacol 9: 461-468.
24. DiFranza JR, Wellman RJ (2007) Sensitization to Nicotine: how the animal literature might inform future human research. Nicotine Tob Res 9: 9-20.
25. Duncan GE, Knapp DJ, Carson SW, Breese GR (1998) Differential effects of chronic antidepressant treatment on swim stress- and fluoxetine-induced secretion of corticosterone and progesterone. J Pharmacol Exp Ther 285: 579-587.
26. Dundon W, Lynch KG, Pettinati HM, Lipkin C (2004) Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol: Clin Exp Res 28: 1065-1073.
27. Fava GA (1994) Do antidepressant and antianxiety drugs increase chronicity in affective disorders? Psychother Psychosom 61: 125-131.
28. Fava GA (1999) Potential sensitising effects of antidepressant drugs on depression. CNS Drugs 12: 247-256.
29. Furukawa TA, Cipriani A, Barbui C, Geddes JR (2007) Long-term treatment of depression with antidepressants: a systematic narrative review. Can J Psychiatry 52: 545-552.
30. Gilman AG, Goodman K, Gilman A (1980) The pharmacological basis of therapeutics. New York: Macmillan Publishing Co.
31. Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand J-P, Soubrié P (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 99: 6370-6375.
32. Gross R (1996) Fluoxetine abuse. J Clin Psychopharmacol 16: 467-468.
33. Haddad P (1999) Do antidepressants have any potential to cause addiction? J Psychopharmacol 13: 300-307.
34. Higley J, Hasert M, Suomi S, Linnoila M (1998) The serotonin reuptake inhibitor sertraline reduces excessive alcohol consumption in nonhuman primates: effect of stress. Neuropsychopharmacology 18: 431-443.
35. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ (1996) The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 66: 17-31.
36. Kranzler HR, Burleson JA, Brown J, Babor TF (2006) Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol: Clin Exp Res 20: 1534-1541.
37. Kurian BT, Ray WA, Arbogast PG, Fuchs DC, Dudley JA, Cooper WO (2007) Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Arch Pediatr Adolesc Med 161: 690-696.
38. Lanteri C, Salomon L, Torrens Y, Glowinski J, Tassin JP (2007) Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism. Neuropsychopharmacology 33: 1724-1734.
39. Laviola G, Adriani W, Terranova ML, Gerra G (1999) Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 23: 993-1010.
40. Le AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of Naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21: 435-444.
41. LeMarquand D, Pihl RO, Benkelfat C (1994) Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol Psychiatry 36: 395-421.
42. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G (2006) Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160: 173-176.
43. Lin D, Koob GF, Markou A (1999) Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat-interactions between the two drugs. Psychopharmacology (Berl) 145: 283-294.
44. Marcussen AB, Flagstad P, Kristjansen PE, Johansen FF, Englund U (2008) Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol Scand 117: 94-100.
45. Medawar C (1997) The antidepressant web - marketing depression and making medicines work. Int J Risk Safety Med 10: 75-126.
46. Menecier P, Menecier-Ossia L, Bern P (1997) Fluoxetine dependence and tolerance. Apropos of a case. Encephale 23: 400-401.
47. Mitchell PJ, Fletcher A (1993) Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm. Neuropharmacology 32: 1001-1009.
48. Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sigg EB (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35: 4493-4497.
49. Naranjo CA, Sellers EM, Lawrin MO (1986) Modulation of ethanol intake by serotonin uptake inhibitors. J Clin Psychiatry 47 (Suppl.): 16-22.
50. National Research Council (2003) Guidelines for the care and use of mammals in neuroscience and behavioral research. Washington DC: The National Academies Press
51. Nemeroff CB, Thase ME (2007) A double-blind, placebocontrolled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 41: 351-359.
52. Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1991) Chronic desipramine enhances amphetamine-induced increases in interstitial concentrations of dopamine in the nucleus accumbens. Eur J Pharmacol 195: 63-73.
53. Olfson M, Marcus SC (2009) National patterns in antidepressant medication treatment. Arch Gen Psychiatry 66: 848-856.
54. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999) Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147: 162-167.
55. Perry P (2007) Psychotropic drug handbook. Baltimore: American Psychiatric Press, Inc
56. Pettinati H, Oslin D, Decker K (2000) Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectr 5: 33-48.
57. Pettinati HM (2004) Antidepressant treatment of co-occurring depression and alcohol dependence. Biol Psychiatry 56: 785.
58. Preskorn SH (1994) Update on antidepressant therapy. J Clin Psychiatry 55 (Suppl A.): 3-5; discussion 98-100.
59. Raja M (2009) Delayed loss of efficacy and depressogenic action of antidepressants. J Clin Psychopharmacol 29: 612-614.
60. Rapport DJ, Calabrese JR (1993) Tolerance to fluoxetine. J Clin Psychopharmacol 13: 361.
61. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK (1990) Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study. J Am Med Assoc 264: 2511-2518.
62. Reneric JP, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136: 190-197.
63. Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF (2000) Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 22: 581-594.
64. Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 (Suppl. 2): S91-S117.
65. Russell VA, Sagvolden T, Johansen EB (2005) Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 1: 9.
66. RxList Inc. (2013) Prozac pharmacology, pharmacokinetics, studies, metabolism. (www.RxList.com).
67. Rygula R, Abumaria N, Domenici E, Hiemke C, Fuchs E (2006) Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats. Behav Brain Res 174: 188-192.
68. Saǧlam E, Uzbay IT, Kayir H, Çelik T, Beyazyürek M (2004) Effects of venlafaxine on ethanol withdrawal syndrome in rats. Fundam Clin Pharmacol 18: 693-698.
69. Samson HH, Sharpe AL, Denning C (1999) Initiation of ethanol self-administration in the rat using sucrose substitution in a sipper-tube procedure. Psychopharmacology (Berl) 147: 274-279.
70. Sattar SP, Grant KM, Bhatia SC (2003) A case of venlafaxine abuse. N Engl J Med 348: 764-765; discussion 764-765.
71. Schramm-Sapyta N, Walker Q, Caster J, Levin E, Kuhn C (2009) Are adolescents more vulnerable to drug addiction than adults? Evidence from animal models. Psychopharmacology 206: 1-21.
72. Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ (2000) Subchronic fluoxetine treatment induces a transient potentiation of amphetamine-induced hyperlocomotion: possible pharmacokinetic interaction. Behav Pharmacol 11: 109-116.
73. Simon O'Brien E, Legastelois R, Houchi H, Vilpoux C, Alaux-Cantin S, Pierrefiche O, Andre E, Naassila M (2011) Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. Neuropsychopharmacology 36: 1518-1530.
74. Sinclair J, Senter R (1967) Increased preference for ethanol in rats following alcohol deprivation. Psychon Sci 8: 11-12.
75. Soeters HS, Howells FM, Russell VA (2008) Methylphenidate does not increase ethanol consumption in a rat model for attention-deficit hyperactivity disorder-the spontaneously hypertensive rat. Metab Brain Dis 23: 303-314.
76. Song JH, Yu BH, Lee D, Yoon SC, Jeon HJ (2011) Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder. Psychiatry Investig 8: 74-76.
77. Spear LP, Brake SC (2004) Peri-adolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 16: 83-109.
78. Tassin JP (2008) Uncoupling between noradrenergic and serotonergic neurons as a molecular basis of stable changes in behavior induced by repeated drugs of abuse. Biochem Pharmacol 75: 85-97.
79. Torrens M, Fonseca F, Mateu G, Farre M (2005) Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 78: 1-22.
80. Ufer M, Meyer SA, Junge O, Selke G, Volz HP, Hedderich J, Gleiter CH (2007) Patterns and prevalence of antidepressant drug use in the German state of Baden-Wuerttemberg: a prescription-based analysis. Pharmacoepidemiol Drug Saf 16: 1153-1160.
81. Willner P (1991) Behavioural models in psychopharmacology: theoretical, industrial and clinical perspectives. pp 89-175. Cambridge: Cambridge University Press